Axogen Inc has a consensus price target of $14.9 based on the ratings of 10 analysts. The high is $20 issued by JMP Securities on May 10, 2023. The low is $9 issued by Leerink Partners on October 16, 2023. The 3 most-recent analyst ratings were released by Raymond James, Canaccord Genuity, and Cantor Fitzgerald on July 1, 2024, June 20, 2024, and January 19, 2024, respectively. With an average price target of $13.33 between Raymond James, Canaccord Genuity, and Cantor Fitzgerald, there's an implied 46.20% upside for Axogen Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/01/2024 | Buy Now | 42.54% | Raymond James | Jayson Bedford | → $13 | Initiates | → Outperform | Get Alert |
06/20/2024 | Buy Now | 64.47% | Canaccord Genuity | Caitlin Cronin | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
01/19/2024 | Buy Now | 31.58% | Cantor Fitzgerald | Ross Osborn | → $12 | Reiterates | Overweight → Overweight | Get Alert |
12/07/2023 | Buy Now | 20.61% | Canaccord Genuity | Caitlin Cronin | → $11 | Reiterates | Buy → Buy | Get Alert |
10/16/2023 | Buy Now | -1.32% | Leerink Partners | Mike Kratky | → $9 | Initiates | → Outperform | Get Alert |
09/26/2023 | Buy Now | 75.44% | Cantor Fitzgerald | Ross Osborn | → $16 | Reiterates | Overweight → Overweight | Get Alert |
08/22/2023 | Buy Now | 75.44% | Cantor Fitzgerald | Travis Steed | → $16 | Reiterates | Overweight → Overweight | Get Alert |
05/10/2023 | Buy Now | 119.3% | JMP Securities | David Turkaly | → $20 | Reiterates | → Market Outperform | Get Alert |
03/28/2023 | Buy Now | 64.47% | Canaccord Genuity | Kyle Rose | → $15 | Reiterates | → Buy | Get Alert |
03/15/2023 | Buy Now | 119.3% | JMP Securities | David Turkaly | → $20 | Reiterates | → Market Outperform | Get Alert |
11/11/2022 | Buy Now | 64.47% | Jefferies | Michael Sarcone | → $15 | Assumes | → Buy | Get Alert |
05/09/2022 | Buy Now | 64.47% | Canaccord Genuity | Kyle Rose | $10 → $15 | Upgrade | Hold → Buy | Get Alert |
05/05/2022 | Buy Now | 53.51% | SVB Leerink | Danielle Antalffy | $12 → $14 | Maintains | Outperform | Get Alert |
11/04/2021 | Buy Now | 119.3% | JMP Securities | — | — | Maintains | Market Outperform | Get Alert |
The latest price target for Axogen (NASDAQ:AXGN) was reported by Raymond James on July 1, 2024. The analyst firm set a price target for $13.00 expecting AXGN to rise to within 12 months (a possible 42.54% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Axogen (NASDAQ:AXGN) was provided by Raymond James, and Axogen initiated their outperform rating.
The last upgrade for Axogen Inc happened on May 9, 2022 when Canaccord Genuity raised their price target to $15. Canaccord Genuity previously had a hold for Axogen Inc.
There is no last downgrade for Axogen.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axogen was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
While ratings are subjective and will change, the latest Axogen (AXGN) rating was a initiated with a price target of $0.00 to $13.00. The current price Axogen (AXGN) is trading at is $9.12, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.